A Phase 1 interventional study of Midazolam and Brigatinib in Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors, sponsored by Takeda. Completed at 14 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-27.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Carcinoma with a site in Italy — 13 open to participants now, 25 under way, 13 of them phase 3. Carcinoma · Italy.
Among the 71 studies in Carcinoma with a site in Italy, this one is the 65th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2019, is one of 2 in phase 1, and was the 38th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →13 of the 71 studies in Carcinoma with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy, United States, Australia and 13 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 17 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 21 more countries
Ages 18+
Pfizer · Sites in Italy, United States, Argentina and 28 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 22 · Phase 3 33 · Phase 4 3
First in 1999; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 245 across the 67 interventional studies, 106 across the 4 observational. Of the 45 that completed or were terminated, 29 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 71 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 3 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT05063565Boston Scientific CorporationTheraSphere With Durvalumab and Tremelimumab for HCC | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 71 studies in Carcinoma with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the effect of repeat-dose administration of brigatinib 180 milligram (mg) once daily (QD) on the single-dose pharmacokinetics (PK) of midazolam.
The study will enroll approximately 20 participants to achieve approximately 15 PK-evaluable participants for assessment. This study will consist of 2 parts: Part A of the study will evaluate the effect of repeat-dose administration of brigatinib on the single-dose PK of midazolam. Part B of the study is exploratory and will allow participants to continue brigatinib until disease progression (PD). All participants will receive study drug via the oral route. Participants will be assigned to: Midazolam 3 mg + Brigatinib 90 mg.
The overall time to participate in this study is 26 months. Participants will have a 28-day PK cycle in Part A and a maximum of 23 cycles in Part B, and a 30-day follow-up period after end of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Locally advanced or solid tumors who meet 1 of the following 4 criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
Drug: Midazolam · Drug: Brigatinib
Midazolam syrup.
Brigatinib tablets.
Also known as: Alunbrig
Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam
The statistical analysis was calculated via a mixed-effects analysis of variance (ANOVA) fitting terms for treatment (midazolam with or without brigatinib coadministration).
Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam
The statistical analysis was calculated via a mixed-effects ANOVA fitting terms for treatment (midazolam with or without brigatinib coadministration).
Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam
Time frame: Cycle 1, Days 1 (Midazolam alone) and 21 (Midazolam + Brigatinib): pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length is 28 days)
Participants took part in the study at 10 investigative sites in the Netherlands, Italy, and Spain from 26 June 2019 to 29 April 2021.
| Milestone | Parts A and B: All Participants |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
| Milestone | Parts A and B: All Participants |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
The statistical analysis was calculated via a mixed-effects analysis of variance (ANOVA) fitting terms for treatment (midazolam with or without brigatinib coadministration).
| hour*nanogram per milliliter (h*ng/mL) | Part A, Cycle 1 Day 1: Midazolam Alone | Part A, Cycle 1 Day 21: Midazolam + Brigatinib |
|---|---|---|
| Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam | 57.2 ± 30.3 | 42.1 ± 54.2 |
The statistical analysis was calculated via a mixed-effects ANOVA fitting terms for treatment (midazolam with or without brigatinib coadministration).
| nanogram per milliliter (ng/mL) | Part A, Cycle 1 Day 1: Midazolam Alone | Part A, Cycle 1 Day 21: Midazolam + Brigatinib |
|---|---|---|
| Part A, Cmax: Maximum Observed Plasma Concentration for Midazolam | 19.7 ± 42.6 | 16.5 ± 49.9 |
| hour | Part A, Cycle 1 Day 1: Midazolam Alone | Part A, Cycle 1 Day 21: Midazolam + Brigatinib |
|---|---|---|
| Part A, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Midazolam | 0.500 (0.220 to 1.93) | 0.500 (0.250 to 1.00) |
Collected over Treatment-emergent adverse events were adverse events (AEs) that started from the first dose of the study drug up to 30 days after the last dose of the study drug (up to Cycle 20 Day 30 ) (Cycle length =28 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Parts A and B: All Participants | 8/24 (33.3%) | 17/24 (70.8%) | 23/24 (95.8%) |
| Event | Parts A and B: All Participants |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/24 |
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/24 |
| Disease progressionGeneral disorders | 2/24 |
| PneumoniaInfections and infestations | 2/24 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/24 |
| Bile duct obstructionHepatobiliary disorders | 1/24 |
| COVID-19Infections and infestations | 1/24 |
| Confusional statePsychiatric disorders | 1/24 |
| HaematuriaRenal and urinary disorders | 1/24 |
| InfectionInfections and infestations | 1/24 |
| Event | Parts A and B: All Participants |
|---|---|
| Blood creatine phosphokinase increasedInvestigations | 11/24 |
| NauseaGastrointestinal disorders | 11/24 |
| DiarrhoeaGastrointestinal disorders | 9/24 |
| Aspartate aminotransferase increasedInvestigations | 8/24 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/24 |
| Alanine aminotransferase increasedInvestigations | 7/24 |
| AnaemiaBlood and lymphatic system disorders | 7/24 |
| VomitingGastrointestinal disorders | 7/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/24 |
| Lipase increasedInvestigations | 6/24 |
Safety population consisted of all participants who received at least 1 dose of any study drug (brigatinib or midazolam).
| Race (NIH/OMB)(Participants) | Parts A and B: All Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Ethnicity (NIH/OMB)(Participants) | Parts A and B: All Participants |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 21 |
| Unknown or Not Reported | 1 |
| Age, Continuous(years) | Parts A and B: All Participants |
|---|---|
| Mean | 56.0 ± 12.08 |
| Sex: Female, Male(Participants) | Parts A and B: All Participants |
|---|---|
| Female | 13 |
| Male | 11 |
| Region of Enrollment(Participants) | Parts A and B: All Participants |
|---|---|
| Italy | 11 |
| Netherlands | 2 |
| Spain | 11 |
| Estimated Glomerular Filtration Rate (eGFR)(mL/min/1.73 m^2) | Parts A and B: All Participants |
|---|---|
| Mean | 97.94 ± 40.596 |
| Height(centimeter (cm)) | Parts A and B: All Participants |
|---|---|
| Mean | 168.7 ± 9.64 |
| Weight(kilogram (kg)) | Parts A and B: All Participants |
|---|---|
| Mean | 73.82 ± 22.415 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2019 to primary completion in Mar 2020, 8 months.
Results were first posted in Jan 2023, 2 years 10 months after primary completion.
Of 41 industry-sponsored phase 1 interventional studies under Carcinoma, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 68. This study's 8 months is below that.
Counting every sponsor, half of 70 studies reached it within 46 months; a quarter within 30 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Brigatinib